EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Genetic and clinical predictors of voriconazole pharmacokinetics and hepatotoxicity: focused on CYP2C19 normal and intermediate metabolizers

Hui Li iD, Qiuya Lu, Beiming Xu, Aiqin Li, Jie Fang, Xiaoshuang He, Xiaolan Bian

Journal of Antimicrobial Chemotherapy · 2026

DOI: 10.1093/jac/dkag065 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2026. Verfasst von Hui Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Antifungal Agents, Chemical and Drug Induced Liver Injury, Cytochrome P-450 CYP2C19, Voriconazole. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Voriconazole is recommended as first-line therapy for invasive fungal infections but exhibits substantial pharmacokinetic (PK) variability and hepatotoxicity. Although CYP2C19 polymorphisms partially explain this variability, evidence regarding additional genetic determinants remains inconsistent. Studies integrating genetic and clinical factors for voriconazole PK and hepatotoxicity are limited.

Objectives

To assess the association between 10 genetic variants and voriconazole trough concentrations in CYP2C19 normal (NM) and intermediate (IM) metabolizers and to identify predictors of PK variability and hepatotoxicity.

Methods

This observational study included 114 adult Chinese patients receiving voriconazole between July 2022 and May 2023. Associations between genetic variants and voriconazole trough concentrations were assessed within CYP2C19 NMs and IMs. Generalized linear models (GLMs) identified predictors of PK variability, and binary logistic regression assessed hepatotoxicity risk.

Results

Voriconazole trough concentrations varied over 40-fold (0.2–9 μg/mL). Nominal associations were observed for CYP3A4 (rs4646437) and NR1I2 (rs7643645, rs3814055) in NMs and for SLCO1B3 (rs4149117), SLCO2B1 (rs3781727) and NR1I2 (rs3814055) in IMs, but none remained significant after Bonferroni correction. GLM analysis identified SLCO1B3 (rs4149117), NR1I2 (rs3814055), albumin, C-reactive protein (CRP) and daily dose as predictors of PK variability. Hepatotoxicity occurred in 27.2% of patients and was associated with higher trough concentrations, whereas the NR1I2 (rs7643645) GG genotype and higher baseline platelet count were associated with reduced risk.

Conclusions

Marked interindividual variability in voriconazole exposure persists among CYP2C19 NMs and IMs. Integrating therapeutic drug monitoring (TDM) with genetic and clinical factors may optimize dosing and reduce hepatotoxicity risk. Larger multicentre studies are still needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antifungal AgentsChemical and Drug Induced Liver InjuryCytochrome P-450 CYP2C19VoriconazoleAdultAgedFemaleHumansMaleMiddle AgedChinaInvasive Fungal Infections

Substanzen

Antifungal AgentsCYP2C19 protein, humanCytochrome P-450 CYP2C19Voriconazole

Autor:innen und Institutionen

  • Department of Pharmacy, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
  • Department of Laboratory Medicine, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
  • Department of Emergency Medicine, Qilu Hospital of Shandong University, Jinan, Shandong, China.
  • Department of Pharmacy, Ruijin Hospital Luwan Branch, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

ORCID-Profile: Hui Li

Förderung

  • National Natural Science Foundation of China
  • National Key Research and Development Program of China

Zitieren

APA

Li, H., Lu, Q., Xu, B., Li, A., Fang, J., He, X., & Bian, X. (2026). Genetic and clinical predictors of voriconazole pharmacokinetics and hepatotoxicity: focused on CYP2C19 normal and intermediate metabolizers. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkag065

Vancouver

Li H, Lu Q, Xu B, Li A, Fang J, He X, et al. Genetic and clinical predictors of voriconazole pharmacokinetics and hepatotoxicity: focused on CYP2C19 normal and intermediate metabolizers. Journal of Antimicrobial Chemotherapy. 2026. doi:10.1093/jac/dkag065

BibTeX
@article{Li2026,
  author = {Li, Hui and Lu, Qiuya and Xu, Beiming and Li, Aiqin and Fang, Jie and He, Xiaoshuang and Bian, Xiaolan},
  title = {Genetic and clinical predictors of voriconazole pharmacokinetics and hepatotoxicity: focused on CYP2C19 normal and intermediate metabolizers},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2026},
  doi = {10.1093/jac/dkag065}
}
Kostenlos starten →